NCT04734665 - Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 5, 2021

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2024

Conditions

Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor

Interventions

DRUG

Niraparib-Bevacizumab

"Niraparib 200mg or 300mg (once daily\[QD\]) Bevacizumab 15mg/kg every 3 weeks (Q3W)~\*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD."

Trial Locations (1)

03722

RECRUITING

Yonsei University College of Medicine, Seoul